# Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

> **NCT00946153** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT00946153
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-24
- **Primary completion:** 2014-06-15
- **Final completion:** 2015-08-13
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946153, "Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00946153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*